Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III FCR vs FC in previously untreated chronic lymphocytic leukemia
2004-002787-15Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jan 2005; status: completed.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2004-002787-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002787-15.